Market research
4XC1.F KalVista Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.11
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4834971032
- Market cap
- 1B
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.11
About
About KalVista Pharmaceuticals, Inc
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4XC1.F discussion.
5 years, 5 months ago
KalVista Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 0.3% below its 200 day moving average.
From a valuation standpoint, the stock is 91.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 117.4.
KalVista Pharmaceuticals, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 8.1% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.0% to $-8M since the same quarter in the previous year.
Based on the above factors, KalVista Pharmaceuticals, Inc gets an overall score of 2/5.